Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure

Bente Brendorp; Hanne Elming; Li Jun; Lars Køber; Christian Torp-Pedersen; DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide

Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure

Bente Brendorp, Hanne Elming, Li Jun, Lars Køber, Christian Torp-Pedersen, DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

12 Citationer (Scopus)

Abstract

Udgivelsesdato: 2002-Mar

Originalsprog	Engelsk
Tidsskrift	European Journal of Heart Failure
Vol/bind	4
Udgave nummer	2
Sider (fra-til)	201-6
Antal sider	5
ISSN	1388-9842
Status	Udgivet - 2002

Bibliografisk note

Keywords: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Long QT Syndrome; Male; Middle Aged; Multivariate Analysis; Observer Variation; Phenethylamines; Potassium Channel Blockers; Prognosis; Reproducibility of Results; Sulfonamides; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left

Citationsformater

@article{b4b2cbe0119511df803f000ea68e967b,

title = "Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure",

abstract = "AIMS: Drug-induced changes in QT dispersion may be a way of detecting harmful repolarisation abnormalities for patients receiving antiarrhythmic drugs affecting ventricular repolarisation. METHODS AND RESULTS: In 463 congestive heart failure (CHF) patients enrolled in the Danish Investigations Of Arrhythmia and Mortality On Dofetilide-CHF (DIAMOND-CHF) study, both pre-treatment and on-treatment day 2-6 QT dispersion was available from standard 12-lead ECGs. Patients were randomised in a double-blind manner to receive either placebo or dofetilide, a new class III antiarrhythmic drug. During a median follow-up of 19 months (minimum 1 year), 179 patients (39%) died (135 patients from cardiac causes). Changes in QT dispersion did not predict all-cause or cardiac mortality for patients treated with dofetilide in multivariate survival analysis (Risk ratio: 1.02, 95% confidence interval: 0.97-1.08, P>0.4). This finding was independent of pre-treatment QT dispersion. Dofetilide caused a small QT dispersion increment of 8 ms, not different from the changes seen in the placebo group (3 ms). CONCLUSION: For patients with CHF and reduced left ventricular systolic function, changes in QT dispersion following treatment with dofetilide do not predict all-cause or cardiac mortality. The dofetilide-induced QT dispersion changes are small and comparable to those seen in placebo treated patients.",

author = "Bente Brendorp and Hanne Elming and Li Jun and Lars K{\o}ber and Christian Torp-Pedersen and {DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide}",

note = "Keywords: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Long QT Syndrome; Male; Middle Aged; Multivariate Analysis; Observer Variation; Phenethylamines; Potassium Channel Blockers; Prognosis; Reproducibility of Results; Sulfonamides; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left",

year = "2002",

language = "English",

volume = "4",

pages = "201--6",

journal = "European Journal of Heart Failure",

issn = "1388-9842",

publisher = "JohnWiley & Sons Ltd",

number = "2",

}

TY - JOUR

T1 - Effect of dofetilide on QT dispersion and the prognostic implications of changes in QT dispersion for patients with congestive heart failure

AU - Brendorp, Bente

AU - Elming, Hanne

AU - Jun, Li

AU - Køber, Lars

AU - Torp-Pedersen, Christian

AU - DIAMOND Study Group. Danish Investigations Of Arrhythmia and Mortality On Dofetilide

N1 - Keywords: Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Double-Blind Method; Electrocardiography; Endpoint Determination; Female; Follow-Up Studies; Heart Failure; Humans; Long QT Syndrome; Male; Middle Aged; Multivariate Analysis; Observer Variation; Phenethylamines; Potassium Channel Blockers; Prognosis; Reproducibility of Results; Sulfonamides; Survival Analysis; Treatment Outcome; Ventricular Dysfunction, Left

PY - 2002

Y1 - 2002

N2 - AIMS: Drug-induced changes in QT dispersion may be a way of detecting harmful repolarisation abnormalities for patients receiving antiarrhythmic drugs affecting ventricular repolarisation. METHODS AND RESULTS: In 463 congestive heart failure (CHF) patients enrolled in the Danish Investigations Of Arrhythmia and Mortality On Dofetilide-CHF (DIAMOND-CHF) study, both pre-treatment and on-treatment day 2-6 QT dispersion was available from standard 12-lead ECGs. Patients were randomised in a double-blind manner to receive either placebo or dofetilide, a new class III antiarrhythmic drug. During a median follow-up of 19 months (minimum 1 year), 179 patients (39%) died (135 patients from cardiac causes). Changes in QT dispersion did not predict all-cause or cardiac mortality for patients treated with dofetilide in multivariate survival analysis (Risk ratio: 1.02, 95% confidence interval: 0.97-1.08, P>0.4). This finding was independent of pre-treatment QT dispersion. Dofetilide caused a small QT dispersion increment of 8 ms, not different from the changes seen in the placebo group (3 ms). CONCLUSION: For patients with CHF and reduced left ventricular systolic function, changes in QT dispersion following treatment with dofetilide do not predict all-cause or cardiac mortality. The dofetilide-induced QT dispersion changes are small and comparable to those seen in placebo treated patients.

AB - AIMS: Drug-induced changes in QT dispersion may be a way of detecting harmful repolarisation abnormalities for patients receiving antiarrhythmic drugs affecting ventricular repolarisation. METHODS AND RESULTS: In 463 congestive heart failure (CHF) patients enrolled in the Danish Investigations Of Arrhythmia and Mortality On Dofetilide-CHF (DIAMOND-CHF) study, both pre-treatment and on-treatment day 2-6 QT dispersion was available from standard 12-lead ECGs. Patients were randomised in a double-blind manner to receive either placebo or dofetilide, a new class III antiarrhythmic drug. During a median follow-up of 19 months (minimum 1 year), 179 patients (39%) died (135 patients from cardiac causes). Changes in QT dispersion did not predict all-cause or cardiac mortality for patients treated with dofetilide in multivariate survival analysis (Risk ratio: 1.02, 95% confidence interval: 0.97-1.08, P>0.4). This finding was independent of pre-treatment QT dispersion. Dofetilide caused a small QT dispersion increment of 8 ms, not different from the changes seen in the placebo group (3 ms). CONCLUSION: For patients with CHF and reduced left ventricular systolic function, changes in QT dispersion following treatment with dofetilide do not predict all-cause or cardiac mortality. The dofetilide-induced QT dispersion changes are small and comparable to those seen in placebo treated patients.

M3 - Journal article

C2 - 11959050

SN - 1388-9842

VL - 4

SP - 201

EP - 206

JO - European Journal of Heart Failure

JF - European Journal of Heart Failure

IS - 2

ER -